These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18158435)

  • 21. Filter survival time and requirement of blood products in patients with severe sepsis receiving drotrecogin alfa (activated) and requiring renal replacement therapy.
    Camporota L; Corno E; Menaldo E; Smith J; Lei K; Beale R; Wyncoll D
    Crit Care; 2008; 12(6):R163. PubMed ID: 19094233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).
    Short MA; Schlichting D; Qualy RL
    Curr Med Res Opin; 2006 Dec; 22(12):2525-40. PubMed ID: 17265595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment.
    Vincent JL; Bernard GR; Beale R; Doig C; Putensen C; Dhainaut JF; Artigas A; Fumagalli R; Macias W; Wright T; Wong K; Sundin DP; Turlo MA; Janes J
    Crit Care Med; 2005 Oct; 33(10):2266-77. PubMed ID: 16215381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
    Sadique MZ; Grieve R; Harrison DA; Cuthbertson BH; Rowan KM
    Crit Care; 2011; 15(5):R228. PubMed ID: 21943177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
    Bernard GR; Macias WL; Joyce DE; Williams MD; Bailey J; Vincent JL
    Crit Care; 2003 Apr; 7(2):155-63. PubMed ID: 12720562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
    Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
    Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression.
    Kalil AC; LaRosa SP
    Lancet Infect Dis; 2012 Sep; 12(9):678-86. PubMed ID: 22809883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [PROWESS, ENHANCE and ADDRESS: clinical implications for the treatment with drotrecogin alfa (activated)].
    Cobas Meyer M; Langenfeld H; Rossaint R; Sablotzki A
    Anaesthesist; 2006 Jun; 55 Suppl 1():16-23. PubMed ID: 16680442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
    Laterre PF; Nelson DR; Macias W; Abraham E; Sashegyi A; Williams MD; Levy M; Levi M; Utterback B; Vincent JL
    J Crit Care; 2007 Jun; 22(2):142-52. PubMed ID: 17548026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy.
    Dhainaut JF;
    Curr Med Res Opin; 2008 Apr; 24(4):1187-97. PubMed ID: 18348744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis.
    Goldstein B; Nadel S; Peters M; Barton R; Machado F; Levy H; Haney DJ; Utterback B; Williams MD; Giroir BP
    Pediatr Crit Care Med; 2006 May; 7(3):200-11. PubMed ID: 16575354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.
    Yan SB; Nelson DR
    Crit Care Med; 2004 May; 32(5 Suppl):S239-46. PubMed ID: 15118525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice.
    Ridley S; Lwin A; Wyncoll D; Lippett S; Watson D; Gunning K; Higgins D
    Eur J Anaesthesiol; 2008 Mar; 25(3):211-6. PubMed ID: 18031590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trials in severe sepsis with drotrecogin alfa (activated).
    Laterre PF
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S5. PubMed ID: 18269692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.
    Green C; Dinnes J; Takeda A; Shepherd J; Hartwell D; Cave C; Payne E; Cuthbertson BH
    Health Technol Assess; 2005 Mar; 9(11):1-126, iii-iv. PubMed ID: 15774234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
    Dhainaut JF; Laterre PF; Janes JM; Bernard GR; Artigas A; Bakker J; Riess H; Basson BR; Charpentier J; Utterback BG; Vincent JL;
    Intensive Care Med; 2003 Jun; 29(6):894-903. PubMed ID: 12712239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis.
    Levy M; Levi M; Williams MD; Antonelli M; Wang D; Mignini MA
    Intensive Care Med; 2009 Jul; 35(7):1196-203. PubMed ID: 19367397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions.
    Gentry CA; Gross KB; Sud B; Drevets DA
    Crit Care Med; 2009 Jan; 37(1):19-25. PubMed ID: 19050637
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
    Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
    Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey.
    Bertolini G; Rossi C; Anghileri A; Livigni S; Addis A; Poole D
    Intensive Care Med; 2007 Mar; 33(3):426-34. PubMed ID: 17325836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.